期刊
INFECTIOUS DISEASES IN CLINICAL PRACTICE
卷 15, 期 5, 页码 324-329出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/IPC.0b013e318142cbbf
关键词
-
资金
- Pfizer
- Merck
- GlaxoSmithKline
- Cubist Pharmaceuticals
Daptomycin, an antibiotic approved for the treatment of soft tissue infections, bacteremia, and right-sided endocarditis, is sometimes used for nonapproved indications when treatment options are limited. We summarize the use of daptomycin in the treatment of 11 cases of bone and/or joint infections. Treatment outcome was successful in 3, unsuccessful in 4, and not evaluable in 4.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据